Karin Jorga - Concepedia

Author

Karin Jorga

Roche (Switzerland)

Also Known As

K Jorga, K M Jorga, K. Jorga, K. M. Jorga, K.M. Jorga, KARIN JORGA, Karin Jorga, Karin M. Jorga

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)Roche (United Kingdom)Université Claude Bernard Lyon 1 La Roche College

About

Karin Jorga is an author at Roche (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1K
2	Immunology	2	2	173
3	Allergy	1	1	113
4	Biostatistics	1	1	17
5	Cell Biology	1	1	12

Karin Jorga

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics Hannah M. Jones, Neil Parrott, Karin Jorga, Clinical Pharmacokinetics Physiologically Based PharmacokineticsPharmacokinetic ModelingPharmacological StudyHuman PharmacokineticsMedicine	2006	344
Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics Laurent Claret, Pascal Girard, Paulo M. Hoff, Journal of Clinical Oncology	2009	266
A Guide to Rational Dosing of Monoclonal Antibodies Shuang Bai, Karin Jorga, Xin Yan, Clinical Pharmacokinetics Rational DosingMedicineImmunologyAntibody ScreeningAutoimmunity	2012	161
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding Richard Graham, Bert L. Lum, Sravanthi Cheeti, Clinical Cancer Research	2011	116
Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa. Jasper Dingemanse, Karin Jorga, G. Zürcher, British Journal of Clinical Pharmacology Molecular PharmacologyMedicinal ChemistryAllergyPharmacological StudyLevodopa Pharmacokinetics	1995	113
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure Eric Snoeck, Pascal Chanu, Marc Lavielle, Clinical Pharmacology & Therapeutics	2010	110
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans* Jasper Dingemanse, Karin Jorga, Monique Schmitt, Clinical Pharmacology & Therapeutics	1995	107
<sup>18</sup>F‐dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease Roberto Ceravolo, Paola Piccini, Dale L. Bailey, Synapse Molecular PharmacologyCentral Comt InhibitorF‐dopa Putamen KiMedicineTwelve Pd Patients	2001	106
Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐<i>O</i>‐methyltransferase Karin Jorga, Bärbel Fotteler, P. Heizmann, British Journal of Clinical Pharmacology	1999	91
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration Neil Buss, Paul Snell, Jürgen Bock, British Journal of Clinical Pharmacology	2001	83

Page 1